Is the therapeutic effect of sotoracib obvious and reliable?

Sotorasib is a targeted therapy drug mainly used to treat KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). KRAS G12C mutation is one of the more common driver mutations in lung cancer. Sotoracib achieves therapeutic effects by specifically inhibiting the activity of KRAS G12C mutant protein. Since the clinical use of sotoraxib, the therapeutic effect has received extensive attention and research.

In clinical trials, sotorasiib showed significant efficacy against KRAS G12C mutation-positive non-small cell lung cancer. One of the major studies was the CodeBreaK 100 clinical trial, which showed that some patients treated with sotoraxib experienced significant tumor shrinkage and some even experienced complete remissions. According to the study results, the objective response rate (ORR) of sotoraxib reached and the majority of patients demonstrated stable disease control. These data indicate that the therapeutic effect of sotorasiib on patients with KRAS G12C mutation-positive lung cancer is significant and reliable.

The side effects of sotorasiib treatment are relatively manageable and well tolerated by most patients. Common side effects include diarrhea, fatigue, nausea, loss of appetite, etc., which are usually mild to moderate, and most side effects can be alleviated with supportive care or adjustment of drug dosage. Serious side effects such as abnormal liver function and cardiovascular problems are relatively rare. Overall, the side effects of sotoraxib are mild and can be better tolerated and managed by patients during treatment.

The therapeutic effect of sotorasiib has been verified by multiple clinical trials, especially for patients with KRAS G12C mutation-positive non-small cell lung cancer. Unlike other targeted lung cancer drugs, sotorasiib specifically targets KRAS G12C mutated lung cancer, which makes its efficacy in specific patient groups more clear and reliable. With further study of the drug, sotorasiib is expected to provide an effective treatment option for more patients with lung cancer, especially those who have failed traditional treatments.

Reference materials:https://www.lumakras.com/